Genomic Analysis Core

项目摘要 基因组分析核心结合了两个NCI CCSG支持设施的专业知识和仪器， DNA测序设施和基因组学设施，为DNA测序提供综合服务。 测序和分子分析。Tapan Ganguly博士，DNA测序设施的主任， 2003年，被任命为综合核心总监。两种共享资源的整合 为Abramson癌症中心（ACC）成员提供更有效的技术访问和清晰度。它还 提供了机会，通过更好的协调提高服务质量和范围， 最大限度地利用资源，避免重复。一支经验丰富、训练有素的专业团队 由两名技术总监领导，提供全方位的基因组和分子生物学服务。这些 服务是必不可少的ACC成员研究特定基因的作用，在正常或异常的细胞 在癌细胞和肿瘤中发现。研究人员能够观察到全球基因表达模式 以及未受影响或肿瘤基因组中的遗传变异性。核心提供测序服务， 两个平台，ABI毛细管测序仪上的金标准桑格测序和半导体测序 离子激流PGM和它的升级版质子毛细管测序仪还可以进行微卫星基因分型 碎片分析。全基因组和靶向分子谱分析在多个平台上进行。 Core支持在Affyssin基因芯片、Luminex FlexMap 3D、Fluidigm上进行定量RNA分析 BioMark HD和ABI 7900实时PCR系统，而DNA谱分析可在Affytron SNP上获得 基因芯片，Fluidigm BioMark HD和ABI 7900。分子生物学服务包括克隆、亚克隆 以及用于小鼠中基因靶向的靶向载体构建。行政协调会成员受益于协商， 在整个项目中提供培训。服务范围沿着核心总监的专业知识 有助于基因发现、功能表征和其他研究问题，以阐明 人类癌症的发病机制。此外，DNA和RNA的分子谱分析以及靶向的 癌症基因的测序可以帮助ACC成员进行癌症诊断、亚分类、风险预测 和选择适当的治疗。117个行政协调会成员在报告所述期间使用了核心数据库（10/01/13- 2014年9月30日），占总核心使用量的36%。CCSG支助占拟议核心预算的15% 其余资金来自退款、赠款/合同和机构支助。 其他机构支持的形式是为购买设备提供资金。

Project Summary The Genomic Analysis Core combines the expertise and instrumentation of two NCI CCSG supported facilities, the DNA Sequencing Facility and the Genomics Facility, to provide an integrated array of services for DNA sequencing and molecular profiling. Tapan Ganguly, PhD, the Director of the DNA Sequencing Facility since 2003, has been appointed Director of the consolidated Core. The integration of the two Shared Resources provides more efficient access and clarity of technologies to Abramson Cancer Center (ACC) members. It also presents opportunities for enhancing the quality and the range of services with better coordination as well as maximizing resource utilization without duplication. A team of highly experienced and trained professionals under two Technical Directors provides a whole spectrum of genomic and molecular biological services. These services are essential to ACC members for studying the role of specific genes in normal or abnormal cellular processes found in cancer cells and tumors. Investigators are able to observe global gene expression pattern in a sample, and genetic variability in an unaffected or tumor genome. The Core offers sequencing service on two platforms, gold standard Sanger sequencing on ABI capillary sequencers, and semiconductor sequencing on Ion Torrent PGM and its upgrade, Proton. The capillary sequencers also enable microsatellite genotyping and fragment analysis. Whole genome and targeted molecular profiling are performed on multiple platforms. The Core supports quantitative RNA profiling on Affymetrix GeneChips, Luminex FlexMap 3D, Fluidigm BioMark HD, and ABI 7900 real-time PCR system while DNA profiling is available on Affymetrix SNP GeneChip, Fluidigm BioMark HD and ABI 7900. The molecular biological services include cloning, subcloning and targeting vector construction for gene targeting in mice. ACC members benefit from consultations and training available throughout their projects. The range of services along with the expertise of the Core Director facilitates gene discovery, functional characterization and other research questions to elucidate the molecular pathogenesis of human cancers. In addition, molecular profiling of DNA and RNA together with targeted sequencing of cancer genes can help ACC members in cancer diagnosis, subclassifications, risk prediction and selection of appropriate therapy. 117 ACC members used the Core in the reporting period (10/01/13- 09/30/14) representing 36% of the total Core usage. CCSG support accounts for 15% of the proposed Core budget with the remaining funding coming from chargebacks, grants/contracts and Institutional support. Additional Institutional support comes in the form of funding for equipment purchase.